TuHURA Biosciences (NASDAQ:HURA - Get Free Report) shares shot up 1.7% on Thursday . The company traded as high as $3.72 and last traded at $3.62. 114,112 shares were traded during mid-day trading, a decline of 59% from the average session volume of 276,926 shares. The stock had previously closed at $3.56.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on HURA shares. RODMAN&RENSHAW upgraded shares of TuHURA Biosciences to a "strong-buy" rating in a research note on Thursday, December 19th. HC Wainwright assumed coverage on TuHURA Biosciences in a research report on Monday, March 3rd. They issued a "buy" rating and a $13.00 target price for the company. Finally, Rodman & Renshaw began coverage on TuHURA Biosciences in a research report on Thursday, December 19th. They set a "buy" rating and a $11.00 price target on the stock.
Read Our Latest Stock Report on HURA
TuHURA Biosciences Stock Performance
The firm's 50 day moving average is $3.52.
Hedge Funds Weigh In On TuHURA Biosciences
A number of large investors have recently made changes to their positions in HURA. Jefferies Financial Group Inc. bought a new position in TuHURA Biosciences in the 4th quarter worth about $54,000. Squarepoint Ops LLC bought a new position in shares of TuHURA Biosciences in the fourth quarter valued at approximately $223,000. OMERS ADMINISTRATION Corp bought a new position in shares of TuHURA Biosciences in the fourth quarter valued at approximately $128,000. Millennium Management LLC purchased a new position in TuHURA Biosciences during the fourth quarter valued at approximately $138,000. Finally, Bank of America Corp DE bought a new stake in TuHURA Biosciences during the 4th quarter worth approximately $59,000. 0.62% of the stock is owned by institutional investors.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
